Isn’t my research enough? Translational Research meets Commercialisation

There is certainly more focus today on connecting medical research to commercialisation outcomes than there was 20 years ago when I undertook my PhD, yet a gap still exists. This gap has spawned the generation of Federal Government initiatives such as MTPConnect[1] and NCRIS[2], amongst others, to promote, invest, and shorten the bridge between medical research and patient outcomes.

Let’s be clear – good research is absolutely fundamental to commercialisation, and there’s plenty of good research around. In Australia, we are top five globally in biotechnology[3] – and have been for three consecutive years – as measured by intellectual property, intensity, enterprise support, workforce/education, productivity, policy and stability.

Good research, however, is only one phase of the commercialisation journey.

If we work with the assumption that you have good research underpinning a potentially great new medicine or medical technology, why might your research not be enough?

Here are just a few reasons why…

  • Challenges in progressing to proof-of-concept or prototype
  • Complexities in scale up to commercial manufacture
  • Toxicity studies reveal unacceptable risks
  • Clinical trials reveal unacceptable efficacy and/or safety profiles
  • The target population or medical condition is unclear
  • The expected return on investment isn’t attractive to potential partner organisations

Translational research is a fairly risky proposition, with risk declining (but not completely removed) during the development phase.  Understanding downstream factors which must complement and align with your research can help you hold a rounded perspective to guide your research towards commercialisation success and great patient outcomes.

Here are a few more tips…

Five questions to help bridge your research to commercialisation outcomes

  • What is your 30 second response to tell me about your research? Is it easily understood by a lay person and does it link to a healthcare outcome?
  • Who are the key stakeholder groups outside my immediate area of research?
  • How much research is enough to present a compelling basis for further development?
  • How protected is my research (think Intellectual Property)?
  • What sources can I consult to help me understand some of the potential downstream development challenges?

Upcoming related articles

  • Isn’t my research enough? – Helpful resources
  • Isn’t my research enough? – Success amongst the learnings



[3] 2018 Annual Report, AusBiotech

In addition to Regulatory and Related Consultung Services, Mary offers industry-readiness programs for people looking to enter the pharma, biopharma, biotech, med tech and wellness organisations. Contact Mary for a complimentary industry-readiness check or discussion on how this program may be applied to your organisation.